Niu Wenqiang, Shao Juan, Yu Benxiang, Liu Guolong, Wang Ran, Dong Hengyang, Che Haijie, Li Lubin
Department of Vascular Surgery, Yantai Yuhuangding Hospital, Yantai, China.
Department of Dermatology, Yantai Yuhuangding Hospital, Yantai, China.
Front Cardiovasc Med. 2022 May 23;9:908747. doi: 10.3389/fcvm.2022.908747. eCollection 2022.
To systematically examine the association between metformin and abdominal aortic aneurysm (AAA) and provide a basis for the treatment of AAA.
Pubmed, Embase, Cochrane Library, and Ovid databases were searched by computer to identify the literature related to metformin and AAA published until February 2022. The literature was screened according to the inclusion and exclusion criteria, data were extracted, and a quality assessment was conducted. The meta-analysis was performed using Stata 16.0 and RevMan 5.3 software.
Seven articles containing a total of 10 cohort studies (85,050 patients) met the inclusion criteria and were included in the review. Meta-analysis showed that metformin can limit the expansion of AAA (MD = - 0.72, 95% CI: - 1.08 ~ -0.37, < 0.00001), as well as reduce AAA repair or AAA rupture-related mortality (OR = 0.80, 95% CI:0.66 ~ 0.96, = 0.02). The difference was statistically significant ( < 0.05).
Metformin can limit the expansion of AAA and reduce the incidence of AAA and postoperative mortality. However, further biological experiments and clinical trials still need to be conducted to support this.
系统研究二甲双胍与腹主动脉瘤（AAA）之间的关联，为AAA的治疗提供依据。
通过计算机检索Pubmed、Embase、Cochrane图书馆和Ovid数据库，以识别截至2022年2月发表的与二甲双胍和AAA相关的文献。根据纳入和排除标准对文献进行筛选，提取数据，并进行质量评估。使用Stata 16.0和RevMan 5.3软件进行荟萃分析。
7篇文章共包含10项队列研究（85,050例患者）符合纳入标准，被纳入综述。荟萃分析表明，二甲双胍可以限制AAA的扩张（MD = - 0.72，95%CI：- 1.08 ~ -0.37，P < 0.00001），以及降低AAA修复或AAA破裂相关的死亡率（OR = 0.80，95%CI：0.66 ~ 0.96，P = 0.02）。差异具有统计学意义（P < 0.05）。
二甲双胍可以限制AAA的扩张，降低AAA的发病率和术后死亡率。然而，仍需要进一步的生物学实验和临床试验来支持这一点。
